Amgen's fourth-quarter profit has soared 39 per cent, as the biologic drugmaker posted higher revenue for nearly all its medicines and trounced analyst expectations for the fifth straight quarter.
The world's biggest biotech drugmaker benefited from reduced operating expenses and restructuring charges, compared with 2014.
The company says net income was $US1.8 billion ($A2.54 billion), or $US2.37 per share, up from $US1.29 billion, or $US1.68 per share.
Adjusted net income was $US1.99 billion, or $US2.61 per share. Analysts surveyed by FactSet expected $US2.29.
Revenue grew 3 per cent to $US5.54 billion, led by Enbrel for immune disorders, Neulasta and Aranesp for anaemia, and osteoporosis injection Prolia.
News that makes sense
Your trusted source for staying up-to-date with the world around you. Get free daily news updates and analysis, straight to your inbox.
Amgen hiked its 2016 forecasts slightly, to earnings per share of $US10.60 to $US11 and revenue of $US22 billion to $US22.5 billion.
